Latest pharma news

Mar 20, 2018

Arbor Biotechnologies shining with new CRISPR enzyme Arbor Biotechnologies is shining with its new CRISPR enzyme and has successfully bagged USD 15.6 million in series A funding. The company has recently announced its first scientific discovery of a new enzyme, Cas13d, a CRISPR-Cas13 enzyme. It could offer advantag...

Mar 06, 2018

Dermira pulling plug on acne drug after phase 3 failure Pharmaceutical company Dermira is pulling the plug on its acne drug (olumacostat glasaretil), after it failed to meet its primary endpoints in a pair of phase 3 trials. The drug was tested in patients aged nine and older with moderate to severe acne vulgaris. ...

Feb 16, 2018

Vertex pharmaceutical’s growth story in biotech with Symdeko’s approval FDA has recently approved Vertex Pharmaceutical’s latest combination treatment, Symdeko, to serve the cystic fibrosis patient population. Symdeko's annual list price has been set at USD 292,000. Symdeko has paired with a fresh corrector, tezacaf...

Feb 06, 2018

Charles River to fuel hit discovery with AstraZeneca high-throughput collaboration After collaborating with AstraZeneca Charles River is now looking forward to strengthening its high-throughput screening capabilities (HTC) with the help of highly advance AstraZeneca technology. Now the company is able to offer the ...

Jan 25, 2018

Pharma startup Bonti has recently grabbed a funding of USD 15 million Managed by Ex-Allergan executives biotech startup Bonti has recently bagged a funding of USD 15.5 million in series C, The Company is focused on developing a new botulinum neurotoxin for both therapeutic and cosmetic uses. Funding will help in the...

Jan 19, 2018

Pandion Therapeutics bags USD 58 million in series A Funding Focused on developing Targeted immune modulator drugs, Pandion Therapeutics has successfully grabbed USD 58 million in series A funding. The company is led by highly experienced professionals. Anthony Coyle (former senior vice president at Pfizer and globa...

Jan 12, 2018

Adapsyn signed a USD 162 million deal with Pfizer for microbe-mining project Adapsyn has recently signed a deal with Pfizer for the microbe-mining with the help of advance platform developed by the Canadian company adapsyn. The technique offers a quick filter for promising candidates with better efficacy. Due to the...

Jan 05, 2018

Centrexion Therapeutics has raised a total of USD 67 million to fund phase 3 pain trial Jeffrey Kindler‘s managed biotech company Centrexion Therapeutics has raised $67 million. The funds will be used to promote nonopioid pain drug candidate CNTX-4975 into a phase 3 trial with patients suffering from knee osteoarth...

Dec 19, 2017

Regeneron/Sanofi’s PD-1 drug candidate will be tested with ISA’s HPV immunotherapy Regeneron and Sanofi’s PD-1 candidate cemiplimab is paired with Dutch biotech ISA Pharma’s human papillomavirus (HPV) targeting drug for testing. The new drug is competing to become the sixth PD-1/PD-L1 drug on the market. Joined with...

Nov 28, 2017

Biohaven Completes Enrollment of Rimegepant in Second Pivotal Phase 3 Clinical Trial for the treatment of Migraine Biohaven Pharmaceutical has recently announced the completion of enrollment of their study BHV3000-302 in Phase 3. The company is examining the safety and efficacy of Rimegepant for the treatment of Mi...